Multiomics Market Report 2026

The multiomics market size has grown rapidly in recent years. It will grow from $3.85 billion in 2025 to $4.52 billion in 2026 at a compound annual growth rate (CAGR) of 17.6%. The growth in the historic period can be attributed to rise in genomic sequencing adoption, early development of transcriptomics tools, increased availability of proteomic analysis platforms, expansion of biomarker identification research, growth in biological data generation.

The multiomics market size is expected to see rapid growth in the next few years. It will grow to $8.07 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to advancements in multiomics platforms, rising demand for personalized medicine, increased integration of ai-based analytics, growing use of metabolomics in clinical settings, expanding multiomics applications in precision agriculture. Major trends in the forecast period include growing adoption of single-cell multiomics, rising integration of multi-layer biological data, increased use of multiomics in early disease diagnostics, expansion of multiomics in drug discovery pipelines, growing application of multiomics in agricultural genomics.

The rising demand for personalized medicine is expected to drive growth in the multiomics market. Personalized medicine tailors healthcare decisions and treatments to individual patients based on their genetic, environmental, and lifestyle factors. Its growing adoption is fueled by technological advancements, increased demand for targeted therapies, and improvements in global healthcare. Multiomics supports personalized medicine by providing comprehensive insights into an individual's genetic, molecular, and metabolic profile, enabling tailored treatment strategies. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, up from six in 2022. Therefore, the rising demand for personalized medicine is propelling the multiomics market.

Major companies in the multiomics market are innovating advanced single-cell multiomics platforms to enable high-throughput studies without compromising sample integrity. Single-cell multiomics platforms integrate multiple omics layers with artificial intelligence, allowing researchers to analyze and interpret complex biological data through machine learning and sophisticated algorithms. For example, in February 2023, Becton, Dickinson, and Company, a US-based medical device company, launched the BD Rhapsody HT Xpress, a high-throughput single-cell multiomics platform. This system allows isolation, barcoding, and analysis of up to eight times more single cells than previous models, accommodating multiple cell types, including stem cells and cancer cells, without sample loss, thereby accelerating discovery and insights.

In July 2024, Anacura, a Belgium-based provider of medical and pharmaceutical analytical services, acquired OHMX.bio for an undisclosed amount. This acquisition strengthens Anacura’s multi-omics capabilities, enhancing its drug-discovery and diagnostics platform. OHMX.bio, a Belgium-based Ghent University spin-off, specializes in advanced “-omics” technologies, combining next-generation sequencing, bioinformatics, and multi-omic analyses to accelerate the development of biologics and advanced therapies, including mRNA vaccines and CAR-T cells.

Major companies operating in the multiomics market are Bayer AG, Thermo Fisher Scientific Inc., Novartis AG, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Shimadzu Corporation, Bruker Corporation, Bio-Techne, Azenta Life Sciences, 10x Genomics, Ginkgo Bioworks, Abcam limited, BioLegend, Oxford Nanopore Technologies Plc, Adaptive Biotechnologies, Pacific Biosciences, Standard BioTools, Parse Biosciences, Mission Bio, CD Genomics, Singleron Biotechnologies, Psomagen, BGI Group.

North America was the largest region in the multiomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the multiomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs in the multiomics market have increased the cost of importing advanced sequencing instruments, reagents, and analytical software, slowing adoption in regions dependent on international supply chains. Research institutions and biotechnology companies are the most affected, particularly in countries with limited domestic manufacturing capacity. However, tariffs have also stimulated local production investments and accelerated regional innovation, creating opportunities for domestic multiomics platform development and reducing long-term reliance on foreign suppliers.

The multiomics market research report is one of a series of new reports that provides multiomics market statistics, including multiomics industry global market size, regional shares, competitors with a multiomics market share, detailed multiomics market segments, market trends and opportunities, and any further data you may need to thrive in the multiomics industry. This multiomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Multiomics refers to the integration and analysis of multiple omics data types, including genomics, transcriptomics, proteomics, metabolomics, and epigenomics, to gain a comprehensive understanding of biological systems. This approach enhances insights into complex diseases, biomarker discovery, and precision medicine.

The main types of multiomics are single-cell multiomics and bulk multiomics. Single-cell multiomics analyzes multiple biological molecules, such as DNA, RNA, proteins, and metabolites, within individual cells. It utilizes various platforms, including genomics, transcriptomics, proteomics, metabolomics, and integrated omics platforms, for applications such as diagnostics, drug discovery and development, personalized medicine, agrigenomics, and more. These tools are used by end users including academic and research organizations, pharmaceutical and biotechnology companies, clinical research organizations, and others.

The multiomics market consists of revenues earned by entities by providing services such as experimental design, sample preparation, data analysis, and data generation. The market value includes the value of related goods sold by the service provider or included within the service offering. The multiomics market also includes sales of instruments, consumables and reagents, microarrays, bioinformatics workstations and servers, and imaging systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.